Health Care/Hospital

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in itsChina phase ...

2022-01-18 21:00 1518

Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors

HONG KONG, Jan. 18, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that Ligufalimab (CD47 monoclonal antibody, research and development code: AK117), the novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody, research an...

2022-01-18 20:44 1983

MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation

HANGZHOU, China, Jan. 18, 2022 /PRNewswire/ -- MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC) for an important class B GPCR drug target, 8 Months After Program Initiation. Historically, the developm...

2022-01-18 17:17 1383

InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355

BEIJING, Jan. 18, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first patient inChina has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies, for th...

2022-01-18 14:51 1950

WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility

* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements. WUXI, China, Jan. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access ...

2022-01-18 10:50 2082

Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules

SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli ...

2022-01-18 10:41 2091

CYMBIOTIKA EXPANDS INTO AUSTRALIAN MARKET WITH LAUNCH OF NEW WEBSITE

Leading nutritional supplement brand reaffirms long-term growth in 2022 with international e-commerce platform launch SAN DIEGO, Jan. 18, 2022 /PRNewswire/ -- Cymbiotika, a leading nutritional supplement brand known for creating pure, clinically-backed supplements, today announced the launch of ...

2022-01-18 05:00 1980

CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment ofRichard John Daly ("M...

2022-01-17 21:50 2323

Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease

SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- On January 13, 2022, Green Valley ( Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (...

2022-01-17 14:29 1214

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA

BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor  JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in pati...

2022-01-17 09:04 1413

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin

TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC ) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of...

2022-01-15 03:30 3682

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

* The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects SHANGHAI and GAITHERSBURG, MD., Jan. 14, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceut...

2022-01-14 21:00 6615

Leading E-commerce Logistics and Fulfillment Brand NextSmartShip Partners with B2B Medical E-commerce Giant LyncMed

SHENZHEN, China, Jan. 13, 2022 /PRNewswire/ -- NextSmartShip , a world-leading fulfillment service provider for global e-commerce sellers, signed a strategic partnership agreement with LyncMed, a major global e-commerce platform for medical instruments. Under this...

2022-01-13 22:40 1823

United Imaging Announces Construction of a World-leading Intelligent R&D and Manufacturing Complex with an Investment of More Than USD 490 million

SHANGHAI, Jan. 13, 2022 /PRNewswire/ -- Recently, the construction of United Imaging's brand new Manufacturing and R&D base of operations officially kicked off. With a total investment ofUSD 490 million and a planned footprint of about 420,000 square meters, the company is creating a modern campu...

2022-01-13 17:43 1866

LYNC2M Sets to Deliver 41.67 Million Pairs of Nitrile Gloves in February for Its Largest Order in 2022 to Date

LONDON, Jan. 13, 2022 /PRNewswire/ -- Leading Chinese consumer to manufacturer (C2M) medical products supply chain platform, LYNC2M Medical Technology (Beijing ) Co., Ltd. ("LYNC2M"), plans to deliver in February of its first batch of 41.67 million sets of nitrile gloves to UK for a public health ...

2022-01-13 15:34 1896

Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference

INCHEON, South Korea, Jan. 12, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually fromJanuary 10th to 13th with leaders from major pharmaceutical and biopharmaceuti...

2022-01-13 08:52 1914

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

* Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 12, 2022 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:678...

2022-01-13 00:00 2055

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient had been dosed in itsChina phase...

2022-01-12 21:00 1595

Gracell Biotechnologies Unveils Innovation Center in U.S.

SUZHOU, China and PALO ALTO, Calif., Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...

2022-01-12 21:00 1402

Bionomics Limited participated in the H.C Wainwright BioConnect Conference

ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually fromJanuary 10-13, 2022. Dr Errol De Souza, Executive C...

2022-01-12 19:00 1771
1 ... 177178179180181182183 ... 278